PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98

mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54

BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87

BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell (2003) 13.47

A landscape of driver mutations in melanoma. Cell (2012) 12.61

High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63

BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem (2008) 4.49

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell (2010) 4.48

Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol (2004) 3.80

Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (2004) 3.47

Oncogene-induced cell senescence--halting on the road to cancer. N Engl J Med (2006) 3.39

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36

PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol (2012) 3.11

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol (2006) 2.87

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47

Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci (1999) 2.45

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett (2008) 2.28

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res (2008) 2.15

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06

Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2010) 2.01

Genetic alterations in signaling pathways in melanoma. Clin Cancer Res (2006) 2.00

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett (2013) 1.72

Malignant melanoma: modern black plague and genetic black box. Genes Dev (1998) 1.67

RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell (2013) 1.60

PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov (2014) 1.58

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell (2016) 1.55

The role of B-RAF in melanoma. Cancer Metastasis Rev (2005) 1.53

Serum and glucocorticoid-regulated protein kinases: variations on a theme. J Cell Biochem (2006) 1.42

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41

Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res (2006) 1.26

Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One (2012) 1.21

PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol (2006) 1.19

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet (2015) 1.15

Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest (2013) 1.12

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem (2013) 1.06

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol (2012) 1.03

BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res (2014) 0.99

A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms. J Invest Dermatol (2013) 0.97

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer (2012) 0.93

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett (2012) 0.89

The fastest Western in town: a contemporary twist on the classic Western blot analysis. J Vis Exp (2014) 0.87

Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett (2012) 0.79

INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget (2015) 0.78